CPHI WORLDWIDE 2017

Continuous manufacturing: suitable excipients & more knowledge required, says Dow

By Flora Southey contact

- Last updated on GMT

gettyimages/sinemaslow
gettyimages/sinemaslow
Drug firms need excipients suited to continuous manufacturing according to Dow, which says a better understanding of how products perform when used in round-the-clock production is required.

Continuous manufacturing is one of the biggest trends in solid form manufacturing, said Dow’s Amina Faham at CPhI Worldwide’s Pre-Connect Congress on Monday.

However, making solid dose forms requires a large amount of excipients, and not enough is known about the impact of raw materials on flow rate consistency and homogeneity in the continuous process, she said.

“Existing excipients may not be able to address all the needs of the continuous process,” ​said Faham

“There is a clear need for excipients that are designed for the purpose of the continuous process,” ​she added.

According to Faham, improved knowledge of raw materials could improve product quality.

“A better understanding and better control of all the key attributes of raw materials – excipients and APIs ​[active pharmaceutical ingredients] – and how they impact the manufacturability, and quality of the final drug product, is needed,” ​she said.

The continuous method – said​ to improve speed and quality in drug production – is gaining support across Europe and the US.

In 2016, the US Food and Drug Administration (FDA) was the first regulator to approve​ Janssen’s continuous manufacturing method for HIV drug Prezista (darunavir).

Since then, Swissmedic and the European Medicines Agency​ (EMA) have also cleared Janssen’s move from the traditional ‘batch’ approach to make Prezista.

Related news

Show more

Related products

show more

Roquette Oral Dose Case Study - Part IV

Roquette Oral Dose Case Study - Part IV

Roquette Pharma Solutions | 04-Dec-2017 | Case Study

Download the latest Roquette case study and learn more on how PEARLITOL® Flash mannitol and starch compound offers inert stability, fast disintegration...

Roquette Oral Dose Case Study - Part III

Roquette Oral Dose Case Study - Part III

Roquette Pharma Solutions | 27-Nov-2017 | Case Study

Download the Case Study to find out how Roquette’s SweetPearl® P 300 DC maltitol technology makes an effervescent tablet solution attractive and palatable...

Roquette Oral Dose Case Study - Part II

Roquette Oral Dose Case Study - Part II

Roquette Pharma Solutions | 06-Nov-2017 | Case Study

Download the case study and learn more on how Roquette’s taste masking technology KLEPTOSE® Linecaps (KL) allows the delivery of an efficient taste masking...

The Solid Dose, Latest News from Colorcon

The Solid Dose, Latest News from Colorcon

Colorcon Inc. | 06-Nov-2017 | Data Sheet

With a commitment to serve customers through product innovation and technical excellence, Colorcon's Solid Dose newsletter brings you the latest insight...

Related suppliers